Bacterial lipopolysaccharide (LPS) induces fever that is mediated by pyrogenic cytokines such as interleukin (IL)-1β. We hypothesized that the anti-inflammatory cytokine IL-10 modulates the febrile response to LPS by suppressing the production of pyrogenic cytokines.
INTRODUCTION
During systemic inflammation various brain-mediated responses occur as part of the acute phase reaction, including fever, sickness behaviour, and activation of the hypothalamuspituitary-adrenal (HPA) axis. Fever is a regulated rise in body temperature which is due to a change in the thermoregulatory setpoint (25) . It is widely accepted that fever is controlled by thermosensitive neurons in the preoptic area of the anterior hypothalamus (POA). The febrile response to systemic inflammation involves the activation of blood monocytes and/or hepatic macrophages (Kupffer cells) by exogenous pyrogens, e.g. bacterial-derived lipopolysaccharide (LPS) or other endotoxins, which results in the production and release of cytokines such as interleukin-1β (IL-1β), IL-6 and tumor necrosis factor-α (TNF-α). These cytokines then act as endogenous pyrogens and signal, directly or indirectly, thermoregulatory neurons in the brain to initiate fever (reviewed in Ref. 25) .
Cytokines produced outside the CNS, signal the brain by multiple routes, including humoral and neural pathways (53) . Blood-borne cytokines may activate meningeal macrophages, cerebral endothelial cells and perivascular microglial cells, thereby eliciting the local production of secondary mediators, such as prostaglandin E 2 (PGE 2 ) and IL-6, that are implicated in fever (10, 17, 56) . Circulating cytokines may also act on cells in circumventricular organs (CVOs), such as the organum vasculosum of the lamina terminalis (OVLT) and the area postrema (AP), which lack a functional blood brain barrier (4, 48) . The neurons located close to these CVOs innervate regions in the hypothalamus involved in thermoregulation. In addition, a role for the vagus nerve has been proposed in transmitting inflammatory signals from the periphery to the brain (21, 22, 42, 49, 61) . Peripherally produced cytokines may activate vagal afferent nerves, that innervate the nucleus of the 3 solitary tract (NTS) in the brainstem, from which catecholaminergic projections lead to the hypothalamus (5, 18, 50) .
Since central administration of pyrogenic cytokines elicit fever in doses lower than those required after peripheral administration (12, 30, 31, 45) , they are suggested to act within the brain. Indeed, irrespective of the exact signalling route, pyrogenic cytokines are produced in the brain following systemic LPS exposure. For instance, IL-1β, TNF-α and IL-6 mRNA and protein are expressed in microglial cells and/or neurons in the brain after peripheral administration of LPS (8, 9, 20, 28, (53) (54) (55) . Furthermore, blocking the action of brain-derived IL-1β or IL-6 by central administration of neutralizing antibodies to these cytokines (24, 46) or the interleukin-1 receptor antagonist (33) attenuates the febrile response to peripheral LPS, suggesting that these brain-derived cytokines play an instrumental role in the febrile response.
Production of pyrogenic cytokines by both peripheral macrophages and glial cells can be inhibited by IL-10 (29, 37, 58) . Recent studies further show that IL-10 inhibits fever induced by systemic LPS administration in rats and mice (32, 36) . Moreover, IL-10 knock-out mice show exacerbated and prolonged febrile responses to LPS (32) and elevated TNF and IL-6 levels in the brain (1). These observations led us to hypothesize that IL-10, by acting on its receptor, may play a role in the control of fever by modulating cytokine production in peripheral organs and/or the brain.
The present study was designed to examine the role and site of action of IL-10 in the febrile response in rats. To elucidate target sites of IL-10, we compared the effects of central (intracerebroventricular, i.c.v.) or peripheral (intravenous, i.v.) administration of recombinant rat IL-10 (rrIL-10) on the febrile response to peripheral injection of LPS. In addition, we evaluated the effect of central administration of rrIL-10 on fever induced by central administration of LPS. To test the hypothesis that the effects of IL-10 on the febrile response involve modulation of the production of pyrogenic cytokines, we assessed the concentrations 4 of IL-1β, TNF-α, and IL-6 in plasma, peripheral tissues (liver, spleen, pituitary) and in the brain (hypothalamus and brainstem). To investigate site-specific expression and LPS-induced regulation of IL-10 receptors, we used quantitative RT-PCR to study mRNA expression of IL-10 receptor (IL-10R1, the ligand-binding chain) in the liver and hypothalamus. The present results show that IL-10 is a site-specific modulator of fever, and can act either in the periphery and the brain by inhibiting local cytokine production.
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MATERIALS AND METHODS
Animals.
Male Wistar rats (Harlan CPB, Horst, The Netherlands) were housed two per cage under controlled temperature (20) (21) (22) o C) and light-dark conditions (lights on 7 a.m., lights off 7 p.m.). Food and water were available ad libitum. At the time of the experiments, the animals had body weigths of 250-300 g. To minimize stress-induced hyperthermia, rats were habituated to experimental procedures by non-invasive handling twice daily for three consecutive days prior to the experiments. The experimental protocol had been approved by the Institutional Committee for Animal Health and Care.
Materials. Lipopolysaccharide (LPS;
Escherichia coli serotype 0128-B12; Sigma, St.
Louis, MO, USA) was dissolved in sterile water, divided in aliquots, and stored at -20 o C.
Prior to administration, appropiate dilutions were made in sterile, pyrogen-free saline (Braun, Melsungen, Germany). Recombinant rat IL-10 (rrIL-10; National Institute for Biological Standards and Control, Potters Bar, UK) (2) was diluted in a vehicle of sterile, pyrogen-free saline containing 0.1 % (w/v) BSA (fatty acid-free, low endotoxin; Sigma).
Surgical procedures. Rats were anesthesized with ketamine (50 mg/kg i.m.; Kombivet, Etten-Leur, The Netherlands) and xylazine (Rompun, 5 mg/kg i.p.; Bayer, Leverkusen, Germany) and a permanent cannula was implanted into the right jugular vein according to Steffens (52) , for continuous i.v. infusion and/or repeated blood sampling. In other groups of animals, a permanent 22-gauge guide cannula with an indwelling dummy cannula (Plastics One, Roanoke, VA, USA) was implanted into the right lateral ventricle of the brain at stereotaxic coordinates: 1.5 mm lateral to the midline, 0.6 mm posterior to bregma, and 3.7 mm under the brain surface. Simultaneously, a battery-operated, temperature-sensitive radio-6 transmitter (Data Sciences Inc., St. Paul, MN, USA) was implanted into the peritoneal cavity of all rats. After surgery, rats were individually housed in macrolon cages (20x30x40 cm) and were allowed to recover for at least 6 days.
Experimental procedures. In a pilot experiment in which serial blood samples were taken from a chronically implanted jugular vein cannula in rats that were given rrIL-10 i.v., plasma levels of IL-10 showed a first order decline with a half-life of plasma IL-10 concentrations of approximately 6 min. Therefore, we decided to deliver IL-10 by continuous infusion to reach steady-state IL-10 concentrations, rather than by bolus injection.
All experiments started between 8.00 a.m. and 10.00 a.m. In rats with a cannula in the lateral ventricle, the dummy cannnula was replaced by a 28-gauge stainless steel injector (Plastics One) just prior to the experiment. Since pilot experiments revealed no differences in temperature responses between vehicle/saline-treated rats and IL-10/saline-treated rats (data not shown), the latter were used as control groups in further experiments.
In experiment 1, groups of rats (total n=8-9) were given vehicle or rrIL-10 (4 µg.h In experiment 2, groups of rats (n=4) were given vehicle or rrIL-10 (100, 300 or 600 ng.h In experiment 3, groups of rats (n=10-11) were given LPS (60 ng/rat) or saline (5 µl/rat during 10 min) into the lateral ventricle in freely moving rats, followed by continuous i.c.v.
infusion of vehicle or rrIL-10 (600 ng.h -1 per rat) at a rate of 5 µl.h Cytokine assays. IL-1β, IL-6 and TNF-α concentrations were measured in plasma and tissue homogenates using ELISAs specific for rat IL-1β (47), rat IL-6 (40) and rat TNF-α (41), respectively. Detection limits of the assays in plasma were 10 pg/ml, 16 pg/ml and 40 pg/ml for IL-1β, IL-6 and TNF-α, respectively. Cytokine levels in homogenates are expressed as pg/mg protein (detection limits 1.5 pg/mg protein for IL-1β and 16 pg/mg protein for IL-6 and TNF-α).
RNA Isolation and cDNA synthesis. Total RNA was isolated from tissue homogenates using the SV Total RNA Isolation System (Promega) as described by the manufacturer.
Concentration and purity of the RNA was determined by measuring the absorbance at 260 nm and 280 nm in a microtiter plate reader (ICN Biomedicals, Zoetermeer, The Netherlands).
One µg of RNA was reverse transcribed into cDNA using the Reverse Transcription System (Promega) with oligo-dT primers and AMV enzyme, according to the manufacturer's Statistical analysis. Body temperature data were analyzed by ANOVA for repeated measurements with treatment as the between subject factor and time as the within subject factor. Post-hoc time-matched comparisons between groups were carried out by Fisher's LSD multiple comparison test. ELISA and quantitative PCR data were analyzed by one-way or two-way ANOVA, followed by Fisher's LSD test. If necessary, data were log-transformed before analysis. Parameters that could not be transformed to meet criteria of ANOVA were tested nonparametrically by the Mann-Whitney U test. Correlations were analyzed using the 10 Pearson correlation test. P values < 0.05 were considered to indicate a significant difference.
The statistical evaluation was carried out by using the NCSS 2000 statistical program. In the brain, IL-1β levels were markedly increased by LPS in the brainstem (~26-fold), but not in the hypothalamus. IL-10 infusion blocked the rise in brainstem IL-1β levels, but had no effect on IL-1β levels in the hypothalamus.
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RESULTS
Experiment
IL-6 plasma levels in rats of the vehicle/LPS group were 76 ± 29 pg/ml, whereas levels in rats of the IL-10/saline and IL-10/LPS groups were below detection limit of the assay (15 pg/ml). TNF-α was only detectable in plasma of 4 out of 6 rats in the vehicle/LPS group (108 ± 29 pg/ml), and levels in rats of the other groups were below detection limit of the assay (40 pg/ml). Thus, IL-10 reduced both IL-6 and TNF-α levels in plasma (Mann-Whitney U test, P < 0.01 and P < 0.05, respectively). In all tissue homogenates, TNF-α and IL-6 levels were below detection limits (16 pg/mg protein).
As illustrated in Figure 6 Data of experiments with the IL-10 doses of 100 and 300 ng/rat are not shown, data of the experiment with the dose of 600 ng/rat are illustrated in Figure 3 . 
Experiment 3 Effects of i.c.v. IL-10 on i.c.v. LPS-induced fever.
Effects of i.c.v. IL-10 on i.c.v. LPS-induced cytokine levels in peripheral and brain tissues.
IL-1β levels were detected in various tissue homogenates of rats sacrificed 3.5 and 6 h after administration of LPS, at the peak and at the end of the febrile response, respectively ( Figure   5 ). Plasma levels of IL-1β remained below detection limit of the assay (10 pg/ml). In the liver, spleen and pituitary gland, no marked differences in IL-1β concentrations were observed between vehicle/LPS-and IL-10/LPS-infused rats. In the hypothalamus, IL-10 infusion significantly reduced IL-1β levels at 3.5 and 6 h after LPS administration by more than 2-fold.
In the brainstem, IL-1β levels in IL-10/LPS-infused rats were markedly lower (~6-fold) than those in vehicle/LPS-infused rats at 6 h after LPS injection. No significant differences were observed in IL-6 and TNF-α levels in plasma and tissue homogenates of vehicle/LPS-treated rats compared to those in IL-10/LPS-treated rats (data not shown). 
DISCUSSION
In the present study, we demonstrate that IL-10 can attenuate the febrile response to LPS both by acting in the CNS and in peripheral targets, depending on the site of the primary inflammatory response. Thus, peripheral administration of IL-10 markedly attenuated the febrile response to peripheral LPS and inhibited LPS-induced production of the endogenous pyrogen IL-1β in peripheral tissues and the brainstem, but not in the hypothalamus.
Conversely, central administration of IL-10 attenuated the hyperthermic response to central, but not to peripheral LPS, and inhibited IL-1β production in the hypothalamus and brainstem, but not in peripheral tissues.
Our findings that intravenous infusion of IL-10 inhibits the febrile response of rats to intravenously given LPS, is consistent with previous data of mice given LPS by an intraperitoneal route (32) . The present data show that IL-10 prevents the tendency of the body temperature to drop short after i.v. LPS administration, which may be reminiscent of the hypothermic phase reported after higher doses of LPS (14, 42) . Because the LPS-induced hypothermia depends on macrophage-derived factors, including cytokines and prostaglandins (14, 59) , we speculate that IL-10 may prevent the initial tendency to hypothermia by suppressing cytokine levels, as seen in mice (32) . The data further show that the second phase of the hyperthermic response is selectively attenuated by circulating IL-10. This cryogenic effect of IL-10 is correlated with decreased levels of circulating IL-1β, TNF-α and IL-6 in plasma, and supports the concept that suppression of circulating levels of IL-1β and other pyrogenic cytokines attenuates the late phase of the febrile response (43, 44) . In contrast, the first hyperthermic phase is not affected by IL-10 infusion and is therefore probably controlled by mechanisms different from those involved in the late phase. 16 Interestingly, the suppressing effect of IL-10 on fever is also associated with decreased concentrations of IL-1β in the liver and the pituitary gland. Presumably, IL-1β production by macrophages in these structures, in particular Kupffer cells in the liver (13) (57) . Since IL-1 receptor type I mRNA is present in the AP (19), this brain structure not only produces IL-1β, but likely also expresses the receptors that are necessary to mediate its effects. Therefore we postulate that the local inhibitory action of IL-10 on IL-1β production in the AP may contribute to a diminished neural input to thermoregulatory centers in the hypothalamus and thereby inhibit the febrile response.
In the hypothalamus, IL-1β concentrations were not affected by LPS, which is somewhat surprising as IL-1β mRNA has been demonstrated in circumventricular organs after administration of LPS (39) . It probably relates to the low dose of LPS (10 µg/kg) used in the present study and/or the time interval studied. This may also explain the absence of detectable levels of TNF-α and IL-6 in tissue homogenates under these conditions. Taken together, our findings suggest that peripherally administered IL-10 attenuates LPSinduced fever by inhibiting the production of pyrogenic cytokines in peripheral tissues and the brainstem and, consequently, interferes with humoral or neural signalling routes of these cytokines to the brain.
Strong IL-1β production in the hypothalamus and brainstem was seen after central administration of LPS, i.e. when the primary inflammatory response is generated within the CNS. This is in accordance with the induction of IL-1β mRNA and bioactivity in the CNS after i.c.v. LPS (15, 23, 38) . Correlation analysis revealed that IL-1β production in the hypothalamus is associated with a febrile response, which shows kinetics different than that observed after peripheral LPS (11, 35 , present study). Interestingly, both the febrile response following central LPS and IL-1β levels in the hypothalamus, but not in peripheral organs, were attenuated by central administration of IL-10, which is in agreement with findings in mice (16) . In addition to the antipyretic effect, central administration of IL-10 also antagonized the effects of i.c.v. LPS on social exploratory behaviour and body weight (6) .
Taken together, our data support the concept that brain-derived IL-1β is involved in fever (33) and possibly other sickness symptoms induced by central administration of LPS.
From the preceding observations we conclude that a local action of IL-10 may be required to have an effect on body temperature under the conditions used. It is thus conceivable that central administration of IL-10, at doses up to 600 ng per rat, does not affect the febrile response to peripherally injected LPS, as central IL-10 does not affect IL-1β production in peripheral tissues, most likely because it does not reach such peripheral targets in sufficient concentrations.
The observed effects of exogenous IL-10 on fever implicates the presence of functional IL-10 receptors. Indeed, IL-10R1 mRNA is constitutively expressed both in peripheral organs (e.g. the liver) and in the hypothalamus. In order to test the hypothesis that IL-10 receptor expression is regulated at specific sites depending on the route of LPS administration, relatively high doses of LPS, but relevant for fever (33, 42) Kupffer cells (27) , on which IL-10 has been shown to inhibit IL-6 production and its own mRNA expression (26, 27) . In the hypothalamus, IL-10 acts most likely on glial cells that are known to exhibit IL-10 receptors (34, unpublished observations), and IL-10 has been shown to be capable of inhibiting IL-1β production in glial cells in vitro (29) .
In conclusion, our data show that IL-10 can modulate brain-mediated fever in response to low doses of LPS. Whether it indeed does so seems dependent on IL-10 reaching its receptors in the compartment where the primary inflammatory response is initiated. The mechanisms mediating the site-specific, antipyretic effects of IL-10 relate to suppression of the production of pyrogenic cytokines, notably IL-1β. Although our data show that IL-10 in the brain can attenuate the production of IL-1β by brain cells, we propose that this mechanism plays a 
